Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography

HeartDrug

Volumn 3, Issue 3, 2003, Pages 141-146

  Gustafsson, Finn ^a,b,c   Badskjær, Jørn ^a   Hansen, Frank Stensgaard ^a   Poulsen, Allan H ^a   Hildebrandt, Per ^b  

^a Copenhagen Gen Practitioners' Lab ^*  (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

ACE inhibitor; Diuretic; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 0345659213     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073839     Document Type: Article

References (31)

1. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-1955.
2. Gustafsson F, Torp-Pedersen C, Brendorp B, Seibaek M, Burchardt H, Kober L: Long-term survival in patients hospitalized with congestive heart failure: Relation to preserved and reduced left ventricular systolic function. Eur Heart J 2003;24:863-870.
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
5. Pitt B, Zannad F, Remme WJ, Cody R, Cas-taigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
6. Fox KF, Cowie MR, Wood DA, Coats AJ, Poole-Wilson PA, Sutton GC: A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail 2000;2:423-429.
7. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
8. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA: Immunoreac-tive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47: 287-296.
9. McDonagh TA, Robb SD, Murdoch DR, Mor-ton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
10. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. JAMA 2002;288:1252-1259.
11. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr: Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
12. Smith H, Pickering RM, Struthers A, Simpson I, Mant D: Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study. BMJ 2000;320: 906-908.
13. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-444.
14. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
15. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-1353.
16. McGeoch G, Lainchbury J, Town GI, Toop L, Espiner E, Richards AM: Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Fail 2002;4:479-483.
17. K022516-Elecsys ProBNP: FDA Approval. http://www.fda.gov/cdrh/pdf2/ k022516.pdf, 2002.
18. Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H: An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J 1994;15:1616-1620.
19. Alam M: The atrioventricular plane displacement as a means of evaluating left ventricular systolic function in acute myocardial infarction. Clin Cardiol 1991;14:588-594.
20. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
21. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE: Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: Cohort study in representative and high risk community populations. BMJ 2002;324:1498.
22. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, Trawinski J, Boesgaard S, Aldershvile J: NT-proBNP: A new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-154.
23. Campbell DJ, Mitchelhill KI, Schlicht SM, Booth RJ: Plasma amino-terminal pro-brain natriuretic peptide: A novel approach to the diagnosis of cardiac dysfunction. J Card Fail 2000;6:130-139.
24. Groenning BA, Nilsson JC, Sondergaard L, Pedersen F, Trawinski J, Baumann M, Larsson HB, Hildebrandt PR: Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002;143:923-929.
25. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J: Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-181.
26. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM: Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-994.
27. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J: Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-197.
28. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ: Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998;317:516-519.
29. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ: Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;138:1126-1132.
30. Nielsen OW, Hilden J, Larsen CT, Hansen JF: Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart 2001;86:172-178.
31. Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22: 1527-1560.